These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19217980)

  • 21. Second line treatment for EGFR wild-type advanced NSCLC: the jury is still out.
    Dafni U; Karlis D; Smit E; Peters S
    Lung Cancer; 2014 Jun; 84(3):314-5. PubMed ID: 24685307
    [No Abstract]   [Full Text] [Related]  

  • 22. Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
    Prescrire Int; 2009 Aug; 18(102):145-7. PubMed ID: 19739343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
    Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
    Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
    Popat S; Barbachano Y; Ashley S; Norton A; O'Brien M
    Lung Cancer; 2008 Feb; 59(2):227-31. PubMed ID: 17920156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CT-2103 extends median survival of high-risk lung cancer patients.
    Oncology (Williston Park); 2003 Dec; 17(12):1804, 1809. PubMed ID: 14723015
    [No Abstract]   [Full Text] [Related]  

  • 27. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
    Thongprasert S; Tinmanee S; Permsuwan U
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
    Jiang J; Huang L; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    Acta Oncol; 2011 May; 50(4):582-8. PubMed ID: 21190510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gefitinib for refractory advanced non-small-cell lung cancer.
    Moriguchi H; Kim TY; Sato C
    Lancet; 2006 Jan; 367(9507):299-300. PubMed ID: 16443032
    [No Abstract]   [Full Text] [Related]  

  • 30. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?
    Baselga J
    J Clin Oncol; 2004 Mar; 22(5):759-61. PubMed ID: 14990627
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
    Lee D
    Clin Lung Cancer; 2005 Sep; 7(2):89-91. PubMed ID: 16179094
    [No Abstract]   [Full Text] [Related]  

  • 32. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-line chemotherapy and beyond for non-small-cell lung cancer.
    Edelman MJ
    Clin Adv Hematol Oncol; 2004 Jun; 2(6):373-8. PubMed ID: 16163207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients.
    Yamamoto N; Nishiwaki Y; Negoro S; Jiang H; Itoh Y; Saijo N; Fukuoka M
    J Thorac Oncol; 2010 Jul; 5(7):1042-7. PubMed ID: 20453692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice.
    Tassinari D; Drudi F; Lazzari-Agli L; Tombesi P; Sartori S
    Ann Oncol; 2010 Feb; 21(2):428-429. PubMed ID: 19920059
    [No Abstract]   [Full Text] [Related]  

  • 36. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
    Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
    Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Salvage therapy in patients with advanced non-small cell lung cancer.
    Bedano PM; Hanna NH
    J Thorac Oncol; 2006 Jul; 1(6):582-7. PubMed ID: 17409922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
    Hanna N
    J Thorac Oncol; 2006 Nov; 1(9):927-8. PubMed ID: 17409973
    [No Abstract]   [Full Text] [Related]  

  • 39. A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.
    Stinchcombe TE; Bůzková P; Choksi J; Taylor M; Bakri K; Gillenwater H; Tynan M; Mears A; Jones PE; Socinski MA
    Lung Cancer; 2006 Jun; 52(3):305-11. PubMed ID: 16638621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer.
    Spitzer G; Socinski MA
    J Clin Oncol; 2015 Feb; 33(5):522-3. PubMed ID: 25584003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.